Seoul Semiconductor’s SunLike Series Natural Spectrum LEDs Adopted by British Lighting Brand WILA for Human-Centric Lighting in Office and Educational Buildings
Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED products and technology, announced that WILA Lighting, specialists in personalised lighting solutions, part of The Nordeon Group, based in Oxfordshire, UK, has adopted Seoul Semiconductor’s SunLike Series natural spectrum LEDs for Visic®, WILA’s new product range.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191001005597/en/
Visic® with SunLike Series natural spectrum LEDs (Graphic: Business Wire)
WILA has developed Visic®, a uniquely shaped recessed ceiling luminaire, which features a human-centric lighting design closely matching the spectrum of natural sunlight. The technology lowers the blue light peak to be similar to sunlight’s spectral curve in order to reduce scattered reflection and glare common in conventional LEDs. This result is achieved with SunLike Series LEDs, an advanced lighting technology that promotes well-being by creating a more healthy and productive working environment in offices and educational buildings.
Visic® is an aesthetically attractive ceiling luminaire with its textured surfaces and soft contours. The luminaire is easy to install with a tool-less plug and play installation. Customised options are also available. The range is extremely efficient, operating up to 162 Llm/W, with a Unified Glare Rating (UGR) that achieves low glare UGR<19 rated in accordance with International Commission on Illumination (CIE) discomfort glare evaluation system. This will enable lighting designers to meet even the most challenging design requirements.
Seoul’s SunLike Series natural spectrum LEDs have been identified as a key light source for promoting human well-being, based on the results of a recent comprehensive sleep study conducted by Prof. Christian Cajochen and his team at the University of Basel in Switzerland. The paper, entitled: “Effect of Daylight LED on Visual Comfort, Melatonin, Mood, Waking Performance, and Sleep,” was published in the Journal of Lighting and Research Technology on March 24, 2019. Quoting from the paper: “We have evidence that a daylight [natural spectrum] LED solution has beneficial effects on visual comfort, daytime alertness, mood, and sleep intensity in healthy volunteers.”
Light sources with SunLike Series LEDs more accurately show the colour of objects as they would appear in natural sunlight. Optimised to natural light spectra and colour rendering of CRI-97 (close to CRI-100 of sunlight), and higher than the CRI-80 of conventional LEDs, SunLike Series LEDs deliver significant benefits in vivid colour, contrast detail, and quality of light consistency.
The SunLike Series LEDs have also achieved the highest level of eye safety certification from the International Commission on Illumination as an RG-1 level light source with no photo-biological risks.
“As the paradigm of lighting shifts to human-centric lighting, there is an increasing demand for healthy light sources for people who spend a lot of time indoors,” said Carlo Romiti, Europe sales Vice President of Seoul Semiconductor. “Beyond the function to illuminate the darkness, light sources with SunLike Series LEDs certainly bring differentiated value to the lighting industry, compared to conventional LEDs.”
Seoul Semiconductor developed SunLike Series natural spectrum LEDs in collaboration with Toshiba Materials’ TRI-R spectrum technology in 2017 as the first LED light source to closely match the spectrum of natural sunlight.
To learn more about Visic® by WILA, please visit:
To learn more about the SunLike Series natural spectrum LEDs, please visit:
# # #
About WILA Lighting
WILA Lighting specialises in personalised lighting solutions. WILA is part of The Nordeon Group and is based in Oxfordshire, UK. WILA responds to project specific requirements with personalised lighting solutions, delivering exceptional customer service and manufacturing flexibility. Leading with innovative products and a commitment to focusing on the customer, design team and end user, WILA creates and manufactures personalised lighting products to fulfil the project design specification.
About Seoul Semiconductor
Seoul Semiconductor develops and commercializes LEDs for automotive, general illumination, specialty lighting, and backlighting markets. As the second-largest LED manufacturer globally excluding the captive market, Seoul Semiconductor holds more than 14,000 patents, offers a wide range of technologies, and mass produces innovative LED products such as SunLike – delivering the world’s best light quality in a next-generation LED enabling human-centric lighting optimized for circadian rhythms; WICOP – a simpler structured package-free LED which provides market leading color uniformity and cost savings at the fixture level, providing high lumen density and design flexibility; NanoDriver Series – the world’s smallest 24W DC LED drivers; Acrich, the world's first high-voltage AC-driven LED technology developed in 2005, including all AC LED-related technologies from chip to module and circuit fabrication, and nPola, a new LED product based on GaN-substrate technology that achieves more than ten times the output of conventional LEDs. UCD constitutes a high color gamut display which delivers more than 90% NTSC. For more information, please visit www.seoulsemicon.com/en.
Seoul Semiconductor Inc.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex and Republic of Ireland Expand Long-Term Cystic Fibrosis Medicines Reimbursement Agreement to Include Triple Combination Therapy for All Eligible Patients Ages 12 and Over Once Licensed13.12.2019 21:55:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today confirmed that, following recent collaborative discussions, it has negotiated an agreement with the Health Service Executive (HSE) in the Republic of Ireland to expand the existing long-term cystic fibrosis (CF) reimbursement agreement to include the triple combination regimen (elexacaftor, tezacaftor and ivacaftor), which is under review and pending approval by the European Medicines Agency, for all eligible patients ages 12 and older in line with the potential future licensed indication. This expands the existing agreement which had already included access to current and future Vertex medicines for people in Ireland with CF of any age who: Have one of the specified mutations as included in the KALYDECO® marketing authorization (G551D, G551S, S549R, G1244E, S1251N, G1349D, S1255P, G178R or S549N) or Are homozygous for the F508del mutation or Are heterozygous for the F508del mutation and have a specified mutation (P67L, D579G, D1
CreditLens™ Solution Receives SOC 2 Attestation Report13.12.2019 18:17:00 EET | Press release
Moody’s Analytics announced today that the CreditLens software-as-a-service (SaaS) solution has received an attestation report from the American Institute of Certified Public Accountants (AICPA) System and Organization Controls (SOC 2). The SOC 2 report details the security and availability of customer data in the CreditLens SaaS solution, and denotes its adherence to the AICPA’s security and availability controls standards. Built on the latest cloud-based technology, the CreditLens platform helps businesses digitally transform their commercial credit processes to make faster and better-informed decisions. It facilitates process automation and helps clients improve their efficiency, reduce errors, and streamline workflows. A SOC 2 report ensures that a company’s information security measures are in line with the unique parameters of today’s cloud requirements. The report addresses a service organization's controls that relate to operations and compliance, as outlined by the AICPA's Tru
CHMP Grants Positive Opinion for Expanded Use of Darzalex®▼ (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone (VTd) for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible13.12.2019 14:47:00 EET | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended broadening the existing marketing authorisation for Darzalex®▼ (daratumumab) to include the use of daratumumab in combination with bortezomib, thalidomide and dexamethasone (VTd) for the treatment of adult patients with newly diagnosed patients with multiple myeloma who are eligible for autologous stem cell transplant (ASCT). The Positive Opinion is supported by data from Part 1 of the Phase 3 CASSIOPEIA (MMY3006) study, published in The Lancet 3 in June 2019, and presented at the 2019 American Society of Clinical Oncology (ASCO) Meeting. Additional information about this study can be found at www.ClinicalTrials.gov (NCT02541383). “Today’s Opinion takes us a step closer to offering the first daratumumab combination regimen to transplant eligible patients, redefining treatment for those people newl
Janssen Receives Positive CHMP Opinion for Expanded Use of Erleada® (apalutamide) for Patients with Metastatic Hormone-Sensitive Prostate Cancer13.12.2019 14:40:00 EET | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending approval for expanding the use of Erleada® (apalutamide) to include the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT).2 The CHMP’s Positive Opinion will now be reviewed by the European Commission (EC), which has the authority to grant approval for the new use of apalutamide. The Positive Opinion is based on data from the Phase 3 TITAN study, which assessed the addition of apalutamide to ADT – the current standard of care in mHSPC – in a broad range of patients with mHSPC, regardless of disease volume, prior treatment with docetaxel or staging at initial diagnosis. The dual primary endpoints of the study were overall survival (OS) and radiographic progression-free survival (rPFS). Ap
German Player Karl Rupprec Wins 2019 Boyaa Poker Tournament Europe13.12.2019 12:24:00 EET | Press release
On December 8, the sixth edition of the BPT (Boyaa Poker Tournament) came to an end. King's Resort in the Czech Republic celebrated this BPT Europe that enjoyed 600 cumulative participants from 20 countries. In the end, Karl Rupprec, from Germany, won the Main Event Championship. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191213005109/en/ (Photo: Business Wire) Highlights of the BPT Europe 2019 final The BPT Europe 2019 Main Event began on December 8 at 2:00 p.m., Czech Republic time. After 9 hours of Texas Poker, players Ondrej Drozd from the Czech Republic and Karl Rupprec from Germany reached the last heads-up. In the end, Karl Rupprec, who started with half of his opponent's chips, reversed the situation with his two nines, winning the championship. Heads-up Highlights: Karl Rupprec pair 9 and Ondrej Drozd 2, 5. The flop was 2, Q, 9, so Karl Rupprec got three of a kind, and Ondrej Drozd got pair 2. Rupprec pretended
Seoul Semiconductor’s SunLike Series Natural Spectrum LEDs Adopted by Italian Designed Architectural Lighting Brand for Motorized Luminaire with Smart Wireless Controls13.12.2019 12:00:00 EET | Press release
Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED technology, announced that it has achieved smart lighting design with SunLike Series natural spectrum LEDs in cooperation with Casambi Technologies Oy (“Casambi”), a leading developer of wireless lighting control systems based on Bluetooth Low Energy (BLE), and it has been adopted for the Italian designed architectural lighting brand formalighting Ltd. (“formalighting”), a global manufacturer of Italian designed architectural lighting systems and solutions for a new product line which offers motorized luminaire with smart wireless controls. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191213005009/en/ SunLike implemented in motion lamps (Photo: Business Wire) The SunLike COB LED packages have been adopted by formalighting for the new fixtures, Moto-Zero 40 Compasso and Moto-Zero 66 Zoom, in track mounted motorized spotlight range. In this sect
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom